Date:
February 21, 2022
Issue #:
1644
Summary:
The FDA has approved remimazolam (Byfavo – Acacia
Pharma), an ultra-short-acting IV benzodiazepine,
for induction and maintenance of sedation in adults
undergoing procedures of up to 30 minutes’ duration.
Pharma), an ultra-short-acting IV benzodiazepine,
for induction and maintenance of sedation in adults
undergoing procedures of up to 30 minutes’ duration.
